What is Leerink Partnrs’ Estimate for BNTC FY2025 Earnings?

Benitec Biopharma Inc. (NASDAQ:BNTC) – Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Benitec Biopharma in a report issued on Wednesday, May 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($1.18) per share for the year, up from their previous forecast of ($1.22). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2025 earnings at ($0.26) EPS and FY2026 earnings at ($1.05) EPS.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12.

Several other analysts have also commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $20.00 price target on shares of Benitec Biopharma in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price target on shares of Benitec Biopharma in a research note on Monday, March 24th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.71.

Benitec Biopharma Stock Up 0.7%

Shares of NASDAQ:BNTC opened at $13.60 on Monday. Benitec Biopharma has a 52-week low of $5.74 and a 52-week high of $16.90. The stock has a market cap of $348.16 million, a P/E ratio of -9.01 and a beta of 0.34. The business has a fifty day moving average of $13.68 and a two-hundred day moving average of $12.04.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L purchased 900,000 shares of the stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $13.00 per share, for a total transaction of $11,700,000.00. Following the acquisition, the director now directly owns 8,793,245 shares of the company’s stock, valued at approximately $114,312,185. The trade was a 11.40% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors have recently modified their holdings of the company. MYDA Advisors LLC increased its holdings in Benitec Biopharma by 4.0% in the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after buying an additional 2,000 shares during the last quarter. Northern Trust Corp boosted its position in shares of Benitec Biopharma by 54.2% during the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock worth $482,000 after acquiring an additional 13,425 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock valued at $448,000 after acquiring an additional 20,597 shares during the last quarter. Lion Point Capital LP raised its position in shares of Benitec Biopharma by 59.0% during the 4th quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 23,000 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Benitec Biopharma during the 4th quarter worth about $452,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.